ｐ５３阻害剤とアポトーシスについて
ｐ５３阻害剤とアポトーシスについてです （論文）
p53阻害剤を使用し、アポトーシスを起こらないようにして、抗がん治療時に正常細胞を防護する際、正常細胞が癌化するのではという問い（Q）
(Q). Insufficiency of p53 is associated with a high risk of spontaneous tumors. The suppression of p53 during antitumor therapy may result in the survival of genetically changed cells in radiosensitive tissues which normally would be eliminated by p53-dependent apoptosis. This can increase the risk of appearance of new tumors.
に対する答えが（A）なのですが、訳しても意味がわかりません． 助けていただけませんでしょうか．
(A). Except for hemopoietic stem cells, the differentiating and differentiated cells of radiosensitive tissues are characterized by sensitivity to p53-dependent apoptosis; the survival of clonogenic cells does not depend on p53. Therefore, the suppression of p53 should not affect the amount of genetically changed cells among the surviving stem cells, and, consequently, such a treatment should not increase the risk of appearance of secondary tumors. For a long time colony-stimulating growth factors have been used during chemotherapy with the purpose of stimulating the recovery of hemopoiesis. However, the therapeutic effect of these factors is more likely to be associated with the inhibition of the p53-dependent apoptosis [91] due to activation of the so-called survival pathways, that is, of the signal pathways responsible for cell survival.
なぜ、アポトーシスを起こらなないようにした正常細胞が癌化しないのかがよくわかりません．
